Petros Katsogiannos

Petros Katsogiannos

Auto-generated profile, based on publicly available information

Petros Katsogiannos

Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2021 in Obesity
Verified
Journal Article
Open access
PDF file
PKPetros Katsogiannos
Petros Katsogiannos
PKPrasad G. Kamble
Prasad G. Kamble
MPMaria J. Pereira
Maria J. Pereira
MSMagnus Sundbom
Magnus Sundbom
PCPer‐Ola Carlsson
Per‐Ola Carlsson
DEDaniel Espes
Daniel Espes
Objective: This study aimed to compare cytokine and adipokine levels in patients with obesity with and without type 2 diabetes (T2D) at baseline and 6 months after Roux‐en‐Y gastric bypass (RYGB) with healthy controls.Methods: A total of 34 patients (21 with T2D) with BMI of 30 to 45 kg/m2 were compared with 25 healthy controls without obesity. Cytokines, adipokines, and peptides of relevance for inflammation and metabolism were analyzed in plasma.Results: Significant decreases in weight and glycated hemoglobin A1c were observed. At baseline, interleukin‐6 (IL‐6), IFN‐β, IL‐18, leptin, and hepatocyte growth factor were higher in all patients with obesity compared with healthy controls. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, and visfatin were also increased, whereas bone morphogenic protein‐4 was decreased. Following RYGB, IL‐6 and hepatocyte growth factor were still increased in both groups compared with controls. In T2D patients, IFN‐β, IL‐27, IL‐1α, IL‐2, regenerating islet‐derived protein 3A, visfatin, and osteopontin were found to be increased. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, leptin, and visfatin remained increased.Conclusions: The altered cytokine profile of patients with obesity persisted after RYGB despite large weight loss and improved metabolic status, thus reflecting an inherent inflammatory state.

23 January 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
PKPetros Katsogiannos
Petros Katsogiannos
PKPrasad G Kamble
Prasad G Kamble
GBGretha J Boersma
Gretha J Boersma
FKF Anders Karlsson
F Anders Karlsson
PLPer Lundkvist
Per Lundkvist
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
Context Roux-en-Y gastric bypass (RYGB) surgery effectively prevents or treats type 2 diabetes (T2D). Adipose tissue (AT) mechanisms may be of importance. Objective To assess the relationship between early changes in whole-body and AT metabolism in surgically treated patients with T2D. Design and Setting A randomized single-center study. Patients Nineteen patients with T2D with body mass index 30 to 45 kg/m2. Interventions Thirteen patients were assessed at baseline and 4 and 24 weeks after RYGB (preceded by a 4-week low-calorie diet) and compared with 6 control patients continuing standard medical treatment: oral glucose tolerance test, subcutaneous AT biopsies for gene expression, adipocyte size, glucose uptake, lipolysis, and insulin action. Results At 4 and 24 weeks post-RYGB, all patients but one had stopped diabetes medication. Fasting glucose, HbA1c, and insulin levels decreased and the Matsuda index increased compared with baseline (P < 0.01 for all), indicating improved whole-body insulin sensitivity. Mean adipocyte size significantly reduced, more at 4 than at 24 weeks; at 4 weeks, glucose uptake per adipocyte was lowered, and isoproterenol-stimulated lipolysis tended to increase, whereas the fold insulin effects on glucose uptake and lipolysis were unchanged. Expression of genes involved in fatty acid oxidation, CPT1b and adiponectin, was increased at 4 weeks, whereas leptin and E2F1 (involved in cell proliferation) were reduced (P < 0.05 for all). Conclusion Glycemic control and in vivo insulin sensitivity improved 4 weeks after RYGB, but adipocyte insulin sensitivity did not change despite a marked reduction in adipocyte size. Thus, mechanisms for a rapid improvement of T2D after RYGB may occur mainly in other tissues than adipose.

26 January 2020 in Endocrine
Verified
Journal Article
Open access
PDF file
PKPetros Katsogiannos
Petros Katsogiannos
PKPrasad G. Kamble
Prasad G. Kamble
UWUrban Wiklund
Urban Wiklund
MSMagnus Sundbom
Magnus Sundbom
DEDaniel Espes
Daniel Espes
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
Objective: To explore the role of hormones and the autonomic nervous system in the rapid remission of diabetes after Roux-en-Y Gastric Bypass (RYGB). Research design and methods: Nineteen obese patients with type 2 diabetes, 7 M/12 F, were randomized (2:1) to RYGB or standard-of-care medical treatment (control). At baseline and 4 and 24 weeks post surgery, fasting blood sampling, OGTT, intravenous arginine challenge, and heart-rate variability (HRV) assessments were performed. Results: At both 4 and 24 weeks post-RYGB the following effects were found: arginine-stimulated insulin secretion was reduced. GLP-1, GIP, and glucagon rise during OGTT was enhanced. IGF-1 and GH levels increased. In addition, total HRV and spectral components PLF (power of low frequency) and PHF (power of high frequency) increased. At 4 weeks, morning cortisol was lower than baseline and 24 weeks. At 24 weeks, NEFA levels during OGTT, and the PLF/PHF ratio decreased. None of these changes were seen in the control group. Conclusions: There were rapid changes within 4 weeks after RYGB: signs of enhanced parasympathetic nerve activity, reduced morning cortisol, and enhanced incretin and glucagon responses to glucose. The findings suggest that neurohormonal mechanisms can contribute to the rapid improvement of insulin resistance and glycemia following RYGB in type 2 diabetes.

17 August 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
PLPer Lundkvist
Per Lundkvist
MPMaria Pereira
Maria Pereira
PKPrasad G Kamble
Prasad G Kamble
PKPetros Katsogiannos
Petros Katsogiannos
ALAnna Maria Langkilde
Anna Maria Langkilde
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
Context Sodium glucose cotransporter-2 (SGLT2) inhibitors can raise glucagon levels, but whether this is mediated via direct effects on islet cells or indirectly via blood glucose lowering is unknown. Objective To assess short-term effects on glucagon and other hormones as well as energy substrates following SGLT2 inhibition and whether such effects are secondary to glucose lowering. Moreover, the impact of adding a dipeptidyl peptidase-4 inhibitor was addressed. Design and Setting A phase IV, single-center, randomized 3-treatment crossover, open-label study. Patients 15 metformin-treated type 2 diabetes patients. Interventions At the three visits patients received a single-dose of dapagliflozin 10mg accompanied by either of the following in randomized order: isoglycemic clamp (experiment DG); saline infusion (experiment D); or saxagliptin 5mg plus saline infusion (experiment DS). Directly after 5-h infusion periods, a 2-h oral glucose tolerance test (OGTT) was performed. Results Glucose and insulin levels were stable in experiment DG and decreased in experiment D (Pdiff <0.001). Glucagon (Pdiff <0.01), glucagon/insulin ratio (Pdiff <0.001), non-esterified fatty acids (Pdiff <0.01), glycerol (Pdiff <0.01) and β-OH-butyrate (Pdiff <0.05) were all lower in DG vs D. In multivariate analysis, change in glucose level was the main predictor of change in glucagon level. In DS, glucagon and active GLP-1 were higher vs D but glucose and insulin did not differ. During OGTT, DS had less glucose rise and greater glucagon fall vs D. Conclusion The degree of glucose lowering markedly contributes to regulation of glucagon and insulin secretion as well as lipid mobilization during short-term SGLT2 inhibition.

4 June 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
KAKristina E Almby
Kristina E Almby
PKPetros Katsogiannos
Petros Katsogiannos
MPMaria J Pereira
Maria J Pereira
FKF Anders Karlsson
F Anders Karlsson
MSMagnus Sundbom
Magnus Sundbom
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
Context Roux-en-Y gastric bypass surgery (RYGB) markedly improves glycemia in patients with type 2 diabetes (T2D), but underlying mechanisms and changes over time are incompletely understood. Objective Integrated assessment of neuroendocrine and metabolic changes over time in T2D patients undergoing RYGB. Design and Setting Follow-up of single-center randomized study. Patients Thirteen patients with obesity and T2D compared to 22 healthy subjects. Interventions Blood chemistry, adipose biopsies, and heart rate variability were obtained before and 4, 24, and 104 weeks post-RYGB. Results After RYGB, glucose-lowering drugs were discontinued and hemoglobin A1c fell from mean 55 to 41 mmol/mol by 104 weeks (P < 0.001). At 4 weeks, morning cortisol (P < 0.05) and adrenocorticotropin (P = 0.09) were reduced by 20%. Parasympathetic nerve activity (heart rate variability derived) increased at 4 weeks (P < 0.05) and peaked at 24 weeks (P < 0.01). C-reactive protein (CRP) and white blood cells were rapidly reduced (P < 0.01). At 104 weeks, basal and insulin-stimulated adipocyte glucose uptake increased by 3-fold vs baseline and expression of genes involved in glucose transport, fatty acid oxidation, and adipogenesis was upregulated (P < 0.01). Adipocyte volume was reduced by 4 weeks and more markedly at 104 weeks, by about 40% vs baseline (P < 0.01). Conclusions We propose this order of events: (1) rapid glucose lowering (days); (2) attenuated cortisol axis activity and inflammation and increased parasympathetic tone (weeks); and (3) body fat and weight loss, increased adipose glucose uptake, and whole-body insulin sensitivity (months-years; similar to healthy controls). Thus, neuroendocrine pathways can partly mediate early glycemic improvement after RYGB, and adipose factors may promote long-term insulin sensitivity and normoglycemia.

12 October 2020 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
PKPetros Katsogiannos
Petros Katsogiannos
EREva Randell
Eva Randell
MSMagnus Sundbom
Magnus Sundbom
ARAndreas Rosenblad
Andreas Rosenblad
JEJan W. Eriksson
Jan W. Eriksson
JLJaneth Leksell
Janeth Leksell
Background: To examine the effects of gastric bypass surgery on health-related quality of life (HRQoL) in obese patients with type 2 diabetes, and to investigate their experiences of life adjustments using quantitative and qualitative methods. Methods: Thirteen patients with type 2 diabetes and obesity, (body mass index, BMI > 30 kg/m2), participating in a randomized clinical trial, completed this sub-study. HRQoL was evaluated before, and at 6 months and 2 years after gastric bypass surgery, using the RAND- 36-item health survey. At 2 years, interviews for in-depth analysis of HRQoL changes were performed. Results: Significant improvement was observed from baseline to 6 months for 2 of the eight health concepts, general health, and emotional well-being. At 2 years, improvements were also seen in physical functioning, energy/fatigue, as well as sustained improvements in general health and emotional well-being. Multiple regression analyses showed mostly non-significant associations between the magnitude of decrease in weight, BMI, and HbA1c during follow-up and improvement in HRQoL. The analyses from qualitative interviews supported a common latent theme “Finding a balance between the experience of the new body weight and self-confidence”. Conclusions: The improved HRQoL after gastric bypass surgery in obese patients with type 2 diabetes was not explained specifically by the magnitude of weight loss, but rather by the participants achieving a state of union between body and consciousness. Trial registration ClinicalTrials.gov Identifier NCT02729246. Date of registration 6 April 2016 – Retrospectively registered https://clinicaltrials.gov/ct2/show/NCT02729246?term=bariglykos&draw=2&rank=1